J Mol Med
Journal of Molecular Medicine (Berlin, Germany)
0946-2716
1432-1440
Springer-Verlag
Berlin/Heidelberg


1820751
17211612
135
10.1007/s00109-006-0135-4
Review


An unexpected new role of mutant Ras: perturbation of human embryonic development

Kratz
Christian P.

+49-761-2704514
christian.kratz@uniklinik-freiburg.de

1
Christian P. Kratz




Niemeyer
Charlotte M.

1

Zenker
Martin

2
Martin Zenker




1
Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University of Freiburg, Mathildenstrasse 1, 79106 Freiburg, Germany 
2
Institute of Human Genetics, University of Erlangen-Nuremberg, 91054 Erlangen, Germany 

9
1
2007

3
2007

85
3
227
235
22
8
2006

27
10
2006

30
10
2006


© Springer-Verlag 2007

RAS
PTPN11
BRAF
KRAS
BRAF
MEK1
MEK2
HRAS
 mutations in Costello syndrome, another clinically related disorder, it has now become clear that Noonan-like features (short stature, relative macrocephaly, facial anomalies, learning difficulties) that are found in these three related disorders are a result of constitutive activation of the Ras–Raf–extracellular signal-regulated and mitogen-activated protein kinase pathway.

Keywords
Noonan syndrome
Cardio–facio–cutaneous syndrome
Costello syndrome
Neurofibromatosis type 1
Ras signaling

issue-copyright-statement
© Springer-Verlag 2007




RAS
 genes
RAS
KRAS
NRAS
HRAS
1
5
2
3
1
Fig. 1
GAPs
61
], republication with permission




RAS
4
G12D
5
RAS
4
].

Noonan syndrome and related disorders
2
6
6
7
8
6
9
10
PTPN11
11
PTPN11
12
PTPN11
12
PTPN11
6
13
14
15
14
14
14
Fig. 2
a
PTPN11
BRAF
HRAS
b
PTPN11
MEK2
HRAS
 G12S, respectively. Facial features become more distinct with age, although the similarities of the three syndromes are still evident. Courtesy of Prof. Rainer König, Frankfurt (images of CFC patients) and Prof. Kerstin Kutsche, Hamburg (images of CS patients)





PTPN11
 also acts as oncogene
16
NRAS
KRAS
NF1
17
19
20
21
22
19
PTPN11
PTPN11
23
24
PTPN11
23
25
PTPN11
26
27
6
25
PTPN11
PTPN11
28
30
31
Ptpn11
D61G/+
32
PTPN11
 mutations is mediated through hyperactive Ras signaling.

Neurofibromatosis type 1
NF1
33
NF1
34
35
36
Nf1
Nf1
37
38
39
NF1
40
].

Additional genes mutated in Noonan syndrome
PTPN11
41
42
46
RAS
KRAS
42
KRAS
PTPN11
KRAS
KRAS
44
46
PTPN11
KRAS
42
42
].
KRAS
46
47
KRAS
48
PTPN11
KRAS
48
KRAS
 accounts for less than 5% of NS cases.

Genes mutated in cardio–facio–cutaneous syndrome
42
48
49
49
44
KRAS
42
46
48
48
BRAF
36
BRAF
MEK1
MEK2
45
PTPN11
RAS
BRAF
50
].

The molecular basis of Costello syndrome
KRAS
HRAS
43
51
53
54
55
56
HRAS
BRAF
57
KRAS
48
HRAS
 as CS.

Neuro–cardio–facial–cutaneous syndrome
42
44
46
RAS
58
3
Fig. 3
61
], republication with permission





Neurofibromatosis Noonan syndrome and NS-like features in neurofibromatosis
59
NF1
PTPN11
60
NF1
40
59
NF1
NF1
NF1
4
Fig. 4
NF1
NF1
 allele





Work in progress
KRAS
BRAF
MEK1
MEK2
HRAS
PTPN11
KRAS
BRAF
MEK1
2
 have been excluded as major NS genes (M.Z., unpublished data).
RAS
 genes and isoforms influence clinical phenotypes when these genes/isoforms are mutated in the germline. It will be crucial to elucidate the structural mechanisms to understand how these new lesions perturb signaling on a molecular level. Characterization of the biological consequences of these mutations will be largely improved by the construction of murine knock-in models.

Note added in proof
SOS1
SOS1
 mutations in approximately 10% of cases with NS: Roberts AE, Araki T, Swanson KD, Montgomery KT, Schiripo TA, Joshi VA, Li L, Yassin Y, Tamburino AM, Neel BG, Kucherlapati RS. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet. 2006 Dec 3; [Epub ahead of print] Tartaglia M, Pennacchio LA, Zhao C, Yadav KK, Fodale V, Sarkozy A, Pandit B, Oishi K, Martinelli S, Schackwitz W, Ustaszewska A, Martin J, Bristow J, Carta C, Lepri F, Neri C, Vasta I, Gibson K, Curry CJ, Siguero JP, Digilio MC, Zampino G, Dallapiccola B, Bar-Sagi D, Gelb BD. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet. 2006 Dec 3; [Epub ahead of print]”.


References
1.
Repasky
GA

Chenette
EJ

Der
CJ


Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis
Trends Cell Biol
2004
14
639
647
10.1016/j.tcb.2004.09.014

15519853


2.
Vetter
IR

Wittinghofer
A


The guanine nucleotide-binding switch in three dimensions
Science
2001
294
1299
1304
10.1126/science.1062023

11701921


3.
Donovan
S

Shannon
KM

Bollag
G


GTPase activating poteins: critical regulators of intracellular signaling
BBA Rev Cancer
2002
1602
23
45

Donovan S, Shannon KM, Bollag G (2002) GTPase activating poteins: critical regulators of intracellular signaling. BBA Rev Cancer 1602:23–45 

4.
Bos
JL


Ras oncogenes in human cancer: a review
Cancer Res
1989
49
4682
4689

2547513


5.
Tuveson
DA

Shaw
AT

Willis
NA

Silver
DP

Jackson
EL

Chang
S

Mercer
KL

Grochow
R

Hock
H

Crowley
D

Hingorani
SR

Zaks
T

King
C

Jacobetz
MA

Wang
L

Bronson
RT

Orkin
SH

DePinho
RA

Jacks
T


Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects
Cancer Cell
2004
5
375
387
10.1016/S1535-6108(04)00085-6

15093544


6.
Tartaglia
M

Gelb
BD


Noonan syndrome and related disorders: genetics and pathogenesis
Annu Rev Genomics Hum Genet
2005
6
45
68
10.1146/annurev.genom.6.080604.162305

16124853


7.
Hennekam
RC


Costello syndrome: an overview
Am J Med Genet C Semin Med Genet
2003
117
42
48
10.1002/ajmg.c.10019

12561057


8.
Kavamura
MI

Peres
CA

Alchorne
MM

Brunoni
D


CFC index for the diagnosis of cardiofaciocutaneous syndrome
Am J Med Genet
2002
112
12
16
10.1002/ajmg.10681

12239713


9.
Burgt
I

Brunner
H


Genetic heterogeneity in Noonan syndrome: evidence for an autosomal recessive form
Am J Med Genet
2000
94
46
51
10.1002/1096-8628(20000904)94:1<46::AID-AJMG10>3.0.CO;2-I

10982482


10.
Jamieson
CR

Burgt
I

Brady
AF

Reen
M

Elsawi
MM

Hol
F

Jeffery
S

Patton
MA

Mariman
E


Mapping a gene for Noonan syndrome to the long arm of chromosome 12
Nat Genet
1994
8
357
359
10.1038/ng1294-357

7894486


11.
Tartaglia
M

Mehler
EL

Goldberg
R

Zampino
G

Brunner
HG

Kremer
H

Burgt
I

Crosby
AH

Ion
A

Jeffery
S

Kalidas
K

Patton
MA

Kucherlapati
RS

Gelb
BD


Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
Nat Genet
2001
29
465
468
10.1038/ng772

11704759


12.
Neel
BG

Gu
H

Pao
L


The ‘Shp’ing news: SH2 domain-containing tyrosine phosphatases in cell signaling
Trends Biochem Sci
2003
28
284
293
10.1016/S0968-0004(03)00091-4

12826400


13.
Digilio
MC

Conti
E

Sarkozy
A

Mingarelli
R

Dottorini
T

Marino
B

Pizzuti
A

Dallapiccola
B


Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene
Am J Hum Genet
2002
71
389
394
10.1086/341528

12058348


14.
Kontaridis
MI

Swanson
KD

David
FS

Barford
D

Neel
BG


PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects
J Biol Chem
2006
281
6785
6792
10.1074/jbc.M513068200

16377799


15.
Tartaglia
M

Martinelli
S

Stella
L

Bocchinfuso
G

Flex
E

Cordeddu
V

Zampino
G

Burgt
I

Palleschi
A

Petrucci
TC

Sorcini
M

Schoch
C

Foa
R

Emanuel
PD

Gelb
BD


Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease
Am J Hum Genet
2006
78
279
290
10.1086/499925

16358218


16.
Niemeyer
CM

Arico
M

Basso
G

Biondi
A

Cantu Rajnoldi
A

Creutzig
U

Haas
O

Harbott
J

Hasle
H

Kerndrup
G

Locatelli
F

Mann
G

Stollmann-Gibbels
B

Veer-Korthof
ET

Wering
E

Zimmermann
M


Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS)
Blood
1997
89
3534
3543

9160658


17.
Flotho
C

Valcamonica
S

Mach-Pascual
S

Schmahl
G

Corral
L

Ritterbach
J

Hasle
H

Arico
M

Biondi
A

Niemeyer
CM


RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML)
Leukemia
1999
13
32
37
10.1038/sj/leu/2401240

10049057


18.
Kalra
R

Paderanga
DC

Olson
K

Shannon
KM


Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras
Blood
1994
84
3435
3439

7949098


19.
Lauchle
JO

Braun
BS

Loh
ML

Shannon
K


Inherited predispositions and hyperactive Ras in myeloid leukemogenesis
Pediatr Blood Cancer
2006
46
579
585
10.1002/pbc.20644

16261595


20.
Braun
BS

Tuveson
DA

Kong
N

Le
DT

Kogan
SC

Rozmus
J

Le Beau
MM

Jacks
TE

Shannon
KM


Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder
Proc Natl Acad Sci U S A
2004
101
597
602
10.1073/pnas.0307203101

14699048


21.
Chan
IT

Kutok
JL

Williams
IR

Cohen
S

Kelly
L

Shigematsu
H

Johnson
L

Akashi
K

Tuveson
DA

Jacks
T

Gilliland
DG


Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease
J Clin Invest
2004
113
528
538
10.1172/JCI200420476

14966562


22.
Bader-Meunier
B

Tchernia
G

Mielot
F

Fontaine
JL

Thomas
C

Lyonnet
S

Lavergne
JM

Dommergues
JP


Occurrence of myeloproliferative disorder in patients with Noonan syndrome
J Pediatr
1997
130
885
889
10.1016/S0022-3476(97)70273-7

9202609


23.
Tartaglia
M

Niemeyer
CM

Fragale
A

Song
X

Buechner
J

Jung
A

Hahlen
K

Hasle
H

Licht
JD

Gelb
BD


Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia
Nat Genet
2003
34
148
150
10.1038/ng1156

12717436


24.
Loh
ML

Vattikuti
S

Schubbert
S

Reynolds
MG

Carlson
E

Lieuw
KH

Cheng
JW

Lee
CM

Stokoe
D

Bonifas
JM

Curtiss
NP

Gotlib
J

Meshinchi
S

Beau
MM

Emanuel
PD

Shannon
KM


Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis
Blood
2004
103
2325
2331
10.1182/blood-2003-09-3287

14644997


25.
Kratz
CP

Niemeyer
CM

Castleberry
RP

Cetin
M

Bergstrasser
E

Emanuel
PD

Hasle
H

Kardos
G

Klein
C

Kojima
S

Stary
J

Trebo
M

Zecca
M

Gelb
BD

Tartaglia
M

Loh
ML


The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease
Blood
2005
106
2183
2185
10.1182/blood-2005-02-0531

15928039


26.
Tartaglia
M

Martinelli
S

Cazzaniga
G

Cordeddu
V

Iavarone
I

Spinelli
M

Palmi
C

Carta
C

Pession
A

Arico
M

Masera
G

Basso
G

Sorcini
M

Gelb
BD

Biondi
A


Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia
Blood
2004
104
307
313
10.1182/blood-2003-11-3876

14982869


27.
Bentires-Alj
M

Paez
JG

David
FS

Keilhack
H

Halmos
B

Naoki
K

Maris
JM

Richardson
A

Bardelli
A

Sugarbaker
DJ

Richards
WG

Du
J

Girard
L

Minna
JD

Loh
ML

Fisher
DE

Velculescu
VE

Vogelstein
B

Meyerson
M

Sellers
WR

Neel
BG


Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia
Cancer Res
2004
64
8816
8820
10.1158/0008-5472.CAN-04-1923

15604238


28.
Schubbert
S

Lieuw
K

Rowe
SL

Lee
CM

Li
X

Loh
ML

Clapp
DW

Shannon
KM


Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells
Blood
2005
106
311
317
10.1182/blood-2004-11-4207

15761018


29.
Mohi
MG

Williams
IR

Dearolf
CR

Chan
G

Kutok
JL

Cohen
S

Morgan
K

Boulton
C

Shigematsu
H

Keilhack
H

Akashi
K

Gilliland
DG

Neel
BG


Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations
Cancer Cell
2005
7
179
191
10.1016/j.ccr.2005.01.010

15710330


30.
Chan
RJ

Leedy
MB

Munugalavadla
V

Voorhorst
CS

Li
Y

Yu
M

Kapur
R


Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor
Blood
2005
105
9
3737
3742
10.1182/blood-2004-10-4002

15644411


31.
Keilhack
H

David
FS

McGregor
M

Cantley
LC

Neel
BG


Diverse biochemical properties of Shp2 mutants: implications for disease phenotypes
J Biol Chem
2005
280
30984
30993
10.1074/jbc.M504699200

15987685


32.
Araki
T

Mohi
MG

Ismat
FA

Bronson
RT

Williams
IR

Kutok
JL

Yang
W

Pao
LI

Gilliland
DG

Epstein
JA

Neel
BG


Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation
Nat Med
2004
10
849
857
10.1038/nm1084

15273746


33.
Side
L

Emanuel
P

Taylor
B

Franklin
J

Thompson
P

Castleberry
R

Shannon
K


Mutations of the NF1 gene in leukemias from children without evidence of neurofibromatosis, type 1
Blood
1998
92
267
273

9639526


34.
Shannon
KM

O’Connell
P

Martin
GA

Paderanga
D

Olson
K

Dinndorf
P

McCormick
F


Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders
N Engl J Med
1994
330
597
601
10.1056/NEJM199403033300903

8302341


35.
Stephens K, Weaver M, Leppig KA, Maruyama K, Emanuel PD, Le Beau MM, Shannon KM (2006) Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies. Blood

36.
Bollag
G

Clapp
DW

Shih
S

Adler
F

Zhang
YY

Thompson
P

Lange
BJ

Freedman
MH

McCormick
F

Jacks
T

Shannon
K


Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells
Nat Genet
1996
12
144
148
10.1038/ng0296-144

8563751


37.
Largaespada
DA

Brannan
CI

Jenkins
NA

Copeland
NG


Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia
Nat Genet
1916
12
137
143
10.1038/ng0296-137

8563750


38.
Le
DT

Kong
N

Zhu
Y

Lauchle
JO

Aiyigari
A

Braun
BS

Wang
E

Kogan
SC

Le Beau
MM

Parada
L

Shannon
KM


Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder
Blood
2004
103
4243
4250
10.1182/blood-2003-08-2650

14982883


39.
Colley
A

Donnai
D

Evans
DG


Neurofibromatosis/Noonan phenotype: a variable feature of type 1 neurofibromatosis
Clin Genet
1996
49
59
64

8740913


40.
Luca
A

Bottillo
I

Sarkozy
A

Carta
C

Neri
C

Bellacchio
E

Schirinzi
A

Conti
E

Zampino
G

Battaglia
A

Majore
S

Rinaldi
MM

Carella
M

Marino
B

Pizzuti
A

Digilio
MC

Tartaglia
M

Dallapiccola
B


NF1 gene mutations represent the major molecular event underlying neurofibromatosis-Noonan syndrome
Am J Hum Genet
2005
77
1092
1101
10.1086/498454

16380919


41.
Zenker
M

Buheitel
G

Rauch
R

Koenig
R

Bosse
K

Kress
W

Tietze
HU

Doerr
HG

Hofbeck
M

Singer
H

Reis
A

Rauch
A


Genotype–phenotype correlations in Noonan syndrome
J Pediatr
2004
144
368
374
10.1016/j.jpeds.2003.11.032

15001945


42.
Schubbert
S

Zenker
M

Rowe
SL

Boll
S

Klein
C

Bollag
G

Burgt
I

Musante
L

Kalscheuer
V

Wehner
LE

Nguyen
H

West
B

Zhang
KY

Sistermans
E

Rauch
A

Niemeyer
CM

Shannon
K

Kratz
CP


Germline KRAS mutations cause Noonan syndrome
Nat Genet
2006
38
331
336
10.1038/ng1748

16474405


43.
Aoki
Y

Niihori
T

Kawame
H

Kurosawa
K

Ohashi
H

Tanaka
Y

Filocamo
M

Kato
K

Suzuki
Y

Kure
S

Matsubara
Y


Germline mutations in HRAS proto-oncogene cause Costello syndrome
Nat Genet
2005
37
1038
1040
10.1038/ng1641

16170316


44.
Niihori
T

Aoki
Y

Narumi
Y

Neri
G

Cave
H

Verloes
A

Okamoto
N

Hennekam
RC

Gillessen-Kaesbach
G

Wieczorek
D

Kavamura
MI

Kurosawa
K

Ohashi
H

Wilson
L

Heron
D

Bonneau
D

Corona
G

Kaname
T

Naritomi
K

Baumann
C

Matsumoto
N

Kato
K

Kure
S

Matsubara
Y


Germline KRAS and BRAF mutations in cardio–facio–cutaneous syndrome
Nat Genet
2006
38
294
296
10.1038/ng1749

16474404


45.
Rodriguez-Viciana
P

Tetsu
O

Tidyman
WE

Estep
AL

Conger
BA

Cruz
MS

McCormick
F

Rauen
KA


Germline mutations in genes within the MAPK pathway cause cardio–facio–cutaneous syndrome
Science
2006
311
1287
1290
10.1126/science.1124642

16439621


46.
Carta
C

Pantaleoni
F

Bocchinfuso
G

Stella
L

Vasta
I

Sarkozy
A

Digilio
C

Palleschi
A

Pizzuti
A

Grammatico
P

Zampino
G

Dallapiccola
B

Gelb
BD

Tartaglia
M


Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype
Am J Hum Genet
2006
79
129
135
10.1086/504394

16773572


47.
Margarit
SM

Sondermann
H

Hall
BE

Nagar
B

Hoelz
A

Pirruccello
M

Bar-Sagi
D

Kuriyan
J


Structural evidence for feedback activation by Ras. GTP of the Ras-specific nucleotide exchange factor SOS
Cell
2003
112
685
695
10.1016/S0092-8674(03)00149-1

12628188


48.
Zenker M, Lehmann K, Schulz AL, Barth CF, Hansmann D, Koenig R, Korinthenberg R, Kreiss-Nachtsheim M, Meinecke P, Morlot S, Mundlos S, Quante AS, Raskin S, Schnabel D, Wehner LE, Kratz CP, Horn D, Kutsche K (2006) Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J Med Genet 2006 Oct 20; [Epub ahead of print]

49.
Stone
JC

Colleton
M

Bottorff
D


Effector domain mutations dissociate p21ras effector function and GTPase-activating protein interaction
Mol Cell Biol
1993
13
7311
7320

8246952


50.
Davies
H

Bignell
GR

Cox
C

Stephens
P

Edkins
S

Clegg
S

Teague
J

Woffendin
H

Garnett
MJ

Bottomley
W

Davis
N

Dicks
E

Ewing
R

Floyd
Y

Gray
K

Hall
S

Hawes
R

Hughes
J

Kosmidou
V

Menzies
A

Mould
C

Parker
A

Stevens
C

Watt
S

Hooper
S

Wilson
R

Jayatilake
H

Gusterson
BA

Cooper
C

Shipley
J

Hargrave
D

Pritchard-Jones
K

Maitland
N

Chenevix-Trench
G

Riggins
GJ

Bigner
DD

Palmieri
G

Cossu
A

Flanagan
A

Nicholson
A

Ho
JW

Leung
SY

Yuen
ST

Weber
BL

Seigler
HF

Darrow
TL

Paterson
H

Marais
R

Marshall
CJ

Wooster
R

Stratton
MR

Futreal
PA


Mutations of the BRAF gene in human cancer
Nature
2002
417
949
954
10.1038/nature00766

12068308


51.
Gripp
KW

Lin
AE

Stabley
DL

Nicholson
L

Scott
CI

Doyle
D

Aoki
Y

Matsubara
Y

Zackai
EH

Lapunzina
P

Gonzalez-Meneses
A

Holbrook
J

Agresta
CA

Gonzalez
IL

Sol-Church
K


HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation
Am J Med Genet A
2006
140
1
7

16329078


52.
Kerr
B

Delrue
MA

Sigaudy
S

Perveen
R

Marche
M

Burgelin
I

Stef
M

Tang
B

Eden
OB

O’Sullivan
J

Sandre-Giovannoli
A

Reardon
W

Brewer
C

Bennett
C

Quarell
O

M’Cann
E

Donnai
D

Stewart
F

Hennekam
R

Cave
H

Verloes
A

Philip
N

Lacombe
D

Levy
N

Arveiler
B

Black
G


Genotype–phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases
J Med Genet
2006
43
401
405
10.1136/jmg.2005.040352

16443854


53.
Estep
AL

Tidyman
WE

Teitell
MA

Cotter
PD

Rauen
KA


HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy
Am J Med Genet A
2006
140
8
16

16372351


54.
Johnson
L

Greenbaum
D

Cichowski
K

Mercer
K

Murphy
E

Schmitt
E

Bronson
RT

Umanoff
H

Edelmann
W

Kucherlapati
R

Jacks
T


K-ras is an essential gene in the mouse with partial functional overlap with N-ras
Genes Dev
1997
11
2468
2481

9334313


55.
Mor
A

Philips
MR


Compartmentalized Ras/MAPK signaling
Annu Rev Immunol
2006
24
771
800
10.1146/annurev.immunol.24.021605.090723

16551266


56.
Rocks
O

Peyker
A

Kahms
M

Verveer
PJ

Koerner
C

Lumbierres
M

Kuhlmann
J

Waldmann
H

Wittinghofer
A

Bastiaens
PI


An acylation cycle regulates localization and activity of palmitoylated Ras isoforms
Science
2005
307
1746
1752
10.1126/science.1105654

15705808


57.
Rauen
KA


Distinguishing Costello versus cardio–facio–cutaneous syndrome: BRAF mutations in patients with a Costello phenotype
Am J Med Genet
2006
140
1681
1683
10.1002/ajmg.a.31315

Rauen KA (2006) Distinguishing Costello versus cardio–facio–cutaneous syndrome: BRAF mutations in patients with a Costello phenotype. Am J Med Genet 140:1681–1683 

58.
Bentires-Alj
M

Kontaridis
MI

Neel
BG


Stops along the RAS pathway in human genetic disease
Nat Med
2006
12
283
285
10.1038/nm0306-283

16520774


59.
Hüffmeier
U

Zenker
M

Hoyer
J

Fahsold
R

Rauch
A


A variable combination of features of Noonan syndrome and neurofibromatosis type I are caused by mutations in the NF1 gene
Am J Med Genet A
2006
140
2749
2756

17103458


60.
Bertola
DR

Pereira
AC

Passetti
F

de Oliveira
PS

Messiaen
L

Gelb
BD

Kim
CA

Krieger
JE


Neurofibromatosis–Noonan syndrome: molecular evidence of the concurrence of both disorders in a patient
Am J Med Genet A
2005
136
242
245

15948193


61.
Kratz
CP

Schubbert
S

Bollag
G

Niemeyer
CM

Shannon
KM

Zenker
M


Germline mutations in components of the Ras signaling pathway in Noonan syndrome and related disorders
Cell Cycle
2006
5
1607
1611

16921267



Abbreviations
CFC syndrome
cardio–facio–cutaneous syndrome


CS
Costello syndrome


GAP
GTPase activating protein


GDP
guanosine diphosphate


GEF
guanosine nucleotide exchange factor


GTP
guanosine triphosphate


JMML
juvenile myelomonocytic leukemia


LS
LEOPARD syndrome


MPD
myeloproliferative disorder


NCFC syndrome
neuro–cardio–facial–cutaneous syndrome


NF1
neurofibromatosis type 1


NFNS
neurofibromatosis–Noonan syndrome


NS
Noonan syndrome


N-SH2
n-terminal src-homology 2 domain


NS/JMML
Noonan syndrome in association with JMML


PTPase
phosphatase domain






